CL2018003537A1 - Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional. - Google Patents

Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.

Info

Publication number
CL2018003537A1
CL2018003537A1 CL2018003537A CL2018003537A CL2018003537A1 CL 2018003537 A1 CL2018003537 A1 CL 2018003537A1 CL 2018003537 A CL2018003537 A CL 2018003537A CL 2018003537 A CL2018003537 A CL 2018003537A CL 2018003537 A1 CL2018003537 A1 CL 2018003537A1
Authority
CL
Chile
Prior art keywords
diseases
muscles
lipids
carbon atoms
nutritional supplement
Prior art date
Application number
CL2018003537A
Other languages
English (en)
Spanish (es)
Inventor
Yuhong Dong
Chun-Hsiung Chang
Shentang Lin
Original Assignee
Sunregen Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare Ag filed Critical Sunregen Healthcare Ag
Publication of CL2018003537A1 publication Critical patent/CL2018003537A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CL2018003537A 2016-06-08 2018-12-07 Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional. CL2018003537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08

Publications (1)

Publication Number Publication Date
CL2018003537A1 true CL2018003537A1 (es) 2019-05-03

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003537A CL2018003537A1 (es) 2016-06-08 2018-12-07 Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.

Country Status (12)

Country Link
US (2) US11406616B2 (OSRAM)
EP (1) EP3468551A4 (OSRAM)
JP (2) JP6872805B2 (OSRAM)
KR (1) KR20190017873A (OSRAM)
CN (2) CN110300581B (OSRAM)
AU (1) AU2017277005B2 (OSRAM)
CL (1) CL2018003537A1 (OSRAM)
MX (1) MX2018015188A (OSRAM)
NZ (1) NZ749389A (OSRAM)
SG (1) SG11201810580PA (OSRAM)
TW (1) TWI749016B (OSRAM)
WO (1) WO2017211274A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
JP7685134B2 (ja) * 2019-11-27 2025-05-29 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
JP2024523429A (ja) * 2021-06-18 2024-06-28 サンレーゲン ヘルスケア エージー ウイルス感染の神経学的合併症の処置と予防のための新規化合物
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JPWO2024075625A1 (OSRAM) * 2022-10-02 2024-04-11

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
EP1289530B1 (en) 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EP1900364B1 (en) 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
WO2004103307A2 (en) 2003-05-20 2004-12-02 Baylor Research Institute Method of use of five and fifteen carbon fatty acids
JP4334956B2 (ja) 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
WO2008039855A2 (en) 2006-09-26 2008-04-03 Baylor Research Institute Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
AU2008318196B2 (en) 2007-11-02 2014-04-10 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
MX348036B (es) 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
SG182414A1 (en) * 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
MY173496A (en) * 2010-02-10 2020-01-29 Oryza Oil & Fat Chemical Co Ltd Age production inhibitor
US20110301238A1 (en) 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
US20110306663A1 (en) 2010-06-14 2011-12-15 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
CN107028926A (zh) * 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
BR112015013349A2 (pt) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
JP6963895B2 (ja) * 2013-08-02 2021-11-10 シュバイツァー モウドゥイ インターナショナル インコーポレイテッド 再構成植物原料を含む食用製品
CA2929601A1 (en) * 2013-11-14 2015-05-21 Karin Borges Neurodegenerative disorders and methods of treatment and diagnosis thereof
CN103641713B (zh) * 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) * 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
CA3004996A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Method for improving cognition

Also Published As

Publication number Publication date
CN110300581B (zh) 2023-09-08
MX2018015188A (es) 2019-08-21
JP2021113204A (ja) 2021-08-05
EP3468551A4 (en) 2020-01-22
US11406616B2 (en) 2022-08-09
KR20190017873A (ko) 2019-02-20
NZ749389A (en) 2022-12-23
CA3026152A1 (en) 2017-12-14
CN117298092A (zh) 2023-12-29
AU2017277005B2 (en) 2022-12-22
CN110300581A (zh) 2019-10-01
TW201801720A (zh) 2018-01-16
EP3468551A1 (en) 2019-04-17
WO2017211274A1 (en) 2017-12-14
JP2019518034A (ja) 2019-06-27
AU2017277005A1 (en) 2019-01-17
US20220362197A1 (en) 2022-11-17
JP6872805B2 (ja) 2021-05-19
TWI749016B (zh) 2021-12-11
US20190255129A1 (en) 2019-08-22
SG11201810580PA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
CL2018003537A1 (es) Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.
CY1120663T1 (el) Dpa-εμπλουτισμενες συνθεσεις ωμεγα-3 πολυακορεστων λιπαρων οξεων σε μορφη ελευθερου οξεος
PE20151771A1 (es) Composiciones nutricionales que contienen un componente neurologico y los usos del mismo
AR097110A1 (es) Composiciones nutricionales que contienen una combinación sinérgica y usos de las mismas
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
MX372724B (es) Formulaciones de acido eicosapentaenoico (epa).
MX355035B (es) Composición de uridina y citidina para uso en la prevención o tratamiento de neurotrauma.
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
MX2015007584A (es) Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
NZ747847A (en) Lipid compositions
WO2014140873A3 (en) Omega- 3 phospholipid supplements for improved brain maturity
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
ES2664518T3 (es) Producto alimenticio saludable que contiene ésteres etílicos de ácidos grasos de aceite de linaza, y procedimiento de obtención del mismo
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
AR110542A1 (es) Composiciones nutricionales que contienen inositol y usos de las mismas
PH12020500511A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
CL2018001782A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter.
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
PL408304A1 (pl) Zastosowanie preparatu fosfolipidowego z żółtek jaj